ITGAX and psoriasis: In IMQ‐induced psoriasis‐like skin lesions, CD11c+MHCII+ DCs were significantly increased (1.19 ± 0.11% vs. 0.38 ± 0.04% in control skin lesions); while in astilbin‐treated mice, CD11c+MHCII+ DCs were significantly reduced in a dose‐dependent manner (0.96 ± 0.078% in the AL group and 0.492 ± 0.08% in the AH group).